Literature DB >> 25595402

Clinical presentation, comorbidities, and age but not female gender predict survival after endovascular repair of abdominal aortic aneurysm.

Peter Gloviczki1, Ying Huang2, Gustavo S Oderich2, Audra A Duncan2, Manju Kalra2, Mark D Fleming2, William S Harmsen2, Thomas C Bower2.   

Abstract

OBJECTIVE: The objective was to study associations between clinical variables, demographic factors, and outcome after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysm (AAA).
METHODS: Data of consecutive patients who underwent EVAR between 1997 and 2011 at a tertiary center were analyzed. Comorbidity scores stratified patients into low/normal-risk (score ≤ 10) or high-risk categories (score > 10). The primary end point was mortality; secondary end points were morbidities, reinterventions, conversions, and ruptures.
RESULTS: The study included 934 patients, 117 women (13%) and 817 men (87%) (mean age, 76 ± 7.3 years; range, 51-99 years). There were 870 (93%) asymptomatic, 36 (3.9%) symptomatic, and 28 (3.0%) ruptured AAAs. The 30-day mortality was 1.4% (13 of 934), 1.0% (9 of 870) for asymptomatic patients, 2.8% (1 of 36) for patients with symptomatic AAAs, and 11% (3 of 28) for patients with ruptured AAAs (P = .004). Clinical presentation with symptoms or rupture was associated with more complications (P = .02), reinterventions (P = .003), and a lower 5-year survival (P = .04). Association between surgical risk, female gender, age, and outcome was studied in 870 asymptomatic patients. Both 30-day mortality and complication rates were higher for high-risk vs low/normal-risk patients (2.3% vs 0.2%, P = .003; 15% vs 10%, P = .04); reintervention rates were equivalent (3.8% vs 4.4%; P = .67). The 30-day mortality and complication rates were similar in women and men (2.8% vs 0.8%, P = .09; 17% vs 11%, P = .11), but reintervention rate was higher in women (8.5% vs 3.5%; P = .02). Follow-up averaged 3.8 years (1 month-13.5 years). In asymptomatic patients, 5-year survival was 74% for low/normal-risk patients and 54% for high-risk patients (P < .001); both had similar rates of freedom from complications (65% vs 63%; P = .24), reinterventions (71% vs 75%; P = .36), or rupture (99.3% vs 99.7%; P = .42). Women had more complications (47% vs 34%; P = .04) and reinterventions than men did (39% vs 26%; P = .02); freedom from rupture was the same (100% vs 99.3%; P = .30). There were eight ruptures, all in asymptomatic patients. In multivariate analysis, high surgical risk and age were associated with all-cause mortality (P < .001); female gender was associated with complications and reinterventions (P < .05) but not mortality.
CONCLUSIONS: Clinical presentation predicts early mortality and complications, age predicts both early and late mortalities after EVAR. Although women had an increased rate of complications and reinterventions, women did not have significantly higher mortality than men.
Copyright © 2015 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25595402     DOI: 10.1016/j.jvs.2014.12.004

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

1.  Sex differences in mortality and morbidity following repair of intact abdominal aortic aneurysms.

Authors:  Sarah E Deery; Peter A Soden; Sara L Zettervall; Katie E Shean; Thomas C F Bodewes; Alexander B Pothof; Ruby C Lo; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-12-13       Impact factor: 4.268

2.  Sex Differences in Outcomes Following Ruptured Abdominal Aortic Aneurysm Repair.

Authors:  Ben Li; Naomi Eisenberg; Miranda Witheford; Thomas F Lindsay; Thomas L Forbes; Graham Roche-Nagle
Journal:  JAMA Netw Open       Date:  2022-05-02

3.  Patient selection and perioperative outcomes are similar between targeted and nontargeted hospitals (in the National Surgical Quality Improvement Program) for abdominal aortic aneurysm repair.

Authors:  Peter A Soden; Sara L Zettervall; Klaas H J Ultee; Jeremy D Darling; John C McCallum; Allen D Hamdan; Mark C Wyers; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-07-25       Impact factor: 4.268

4.  Conversion from endovascular to open abdominal aortic aneurysm repair.

Authors:  Klaas H J Ultee; Peter A Soden; Sara L Zettervall; Jeremy Darling; Hence J M Verhagen; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2016-07       Impact factor: 4.268

Review 5.  Abdominal aortic aneurysms in women.

Authors:  Ruby C Lo; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2015-12-30       Impact factor: 4.268

6.  Endovascular Abdominal Aneurysm Repair in Women: What are the Differences Between the Genders?

Authors:  Rui Machado; Gabriela Teixeira; Pedro Oliveira; Luís Loureiro; Carlos Pereira; Rui Almeida
Journal:  Braz J Cardiovasc Surg       Date:  2016 May-Jun

7.  Risk factors for postoperative complications in total thyroidectomy: A retrospective, risk-adjusted analysis from the National Surgical Quality Improvement Program.

Authors:  Lisa Caulley; Stephanie Johnson-Obaseki; Lindy Luo; Hedyeh Javidnia
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

8.  What factors counteract mid-term survival following endovascular repair of abdominal aortic aneurysms?

Authors:  Ertekin Utku Ünal; Hakkı Zafer İscan; Bekir Bogachan Akkaya; İsa Civelek; Mehmet Karahan; Ece Celikten; Göktan Askin; Hayrettin Levent Mavioğlu; Mehmet Ali Özatik
Journal:  Kardiochir Torakochirurgia Pol       Date:  2021-05-15

9.  Outcomes after EVAR in females are similar to males.

Authors:  Naim Boran Tumer; Goktan Askin; Bekir Bogachan Akkaya; Isa Civelek; Ertekin Utku Unal; Hakki Zafer Iscan
Journal:  BMC Cardiovasc Disord       Date:  2021-06-15       Impact factor: 2.298

Review 10.  Long-term efficacy of endovascular vs open surgical repair for complicated type-B aortic dissection: a single-center retrospective study and meta-analysis.

Authors:  Y Zhu; B Wang; Q Meng; J Liu; S Zhai; J He
Journal:  Braz J Med Biol Res       Date:  2016-05-31       Impact factor: 2.590

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.